-
1
-
-
0036598634
-
Bioequivalence and the immunogenicity of biopharmaceuticals
-
Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals.NatRevDrugDiscov 2002; 1 (6): 457-62
-
(2002)
Nat Rev Drug Discov
, vol.1
, Issue.6
, pp. 457-462
-
-
Schellekens, H.1
-
2
-
-
33644865904
-
Early development of therapeutic biologicspharmacokinetics
-
Baumann A. Early development of therapeutic biologicspharmacokinetics. Curr Drug Metab 2006; 7 (1): 15-21
-
(2006)
Curr Drug Metab
, vol.7
, Issue.1
, pp. 15-21
-
-
Baumann, A.1
-
3
-
-
77956334120
-
Mapping the safety profile of biologicals: A disproportionality analysis using the WHO adverse drug reaction database VigiBase
-
Giezen TJ, Mantel-Teeuwisse AK, Meyboom RH, et al. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Drug Saf 2010; 33 (10): 865-78
-
Drug Saf 2010
, vol.33
, Issue.10
, pp. 865-878
-
-
Giezen, T.J.1
Mantel-Teeuwisse, A.K.2
Meyboom, R.H.3
-
4
-
-
33745786806
-
Adverse side-effects to biological agents
-
Pichler WJ. Adverse side-effects to biological agents. Allergy 2006; 61 (8): 912-20
-
(2006)
Allergy
, vol.61
, Issue.8
, pp. 912-920
-
-
Pichler, W.J.1
-
5
-
-
70449709036
-
Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval
-
Giezen TJ, Mantel-Teeuwisse AK, Straus SM, et al. Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval. Drug Saf 2009; 32 (12): 1175-87
-
(2009)
Drug Saf
, vol.32
, Issue.12
, pp. 1175-1187
-
-
Giezen, T.J.1
Mantel-Teeuwisse, A.K.2
Straus, S.M.3
-
6
-
-
54349091558
-
Safetyrelated regulatory actions for biologicals approved in the United States and the European Union
-
Giezen TJ, Mantel-Teeuwisse AK, Straus SM, et al. Safetyrelated regulatory actions for biologicals approved in the United States and the European Union. JAMA 2008; 300 (16): 1887-96
-
(2008)
JAMA
, vol.300
, Issue.16
, pp. 1887-1896
-
-
Giezen, T.J.1
Mantel-Teeuwisse, A.K.2
Straus, S.M.3
-
7
-
-
77952855654
-
A decade of safetyrelated regulatory action in the Netherlands: A retrospective analysis of direct healthcare professional communications from 1999 to 2
-
Mol PG, Straus SM, Piening S, et al. A decade of safetyrelated regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2 Drug Saf 2010; 33 (6): 463-74
-
(2010)
Drug Saf
, vol.33
, Issue.6
, pp. 463-474
-
-
Mol, P.G.1
Straus, S.M.2
Piening, S.3
-
8
-
-
79751511440
-
-
European Medicines Agency [online] [Accessed 2011 Aug 2]
-
European Medicines Agency (2008). Volume 9A of The Rules Governing Medicinal Products in the European Union [online]. Available from URL: http://ec.europa.eu/en terprise/pharmaceuticals/eudralex/vol-9/pdf/vol9a-09- 2008.pdf [Accessed 2011 Aug 2]
-
(2008)
Volume 9A of the Rules Governing Medicinal Products in the European Union
-
-
-
9
-
-
0030787821
-
Principles of signal detection in pharmacovigilance
-
Meyboom RH, Egberts AC, Edwards IR, et al. Principles of signal detection in pharmacovigilance. Drug Saf 1997; 16 (6): 355-65
-
(1997)
Drug Saf
, vol.16
, Issue.6
, pp. 355-365
-
-
Meyboom, R.H.1
Egberts, A.C.2
Edwards, I.R.3
-
10
-
-
0035038538
-
The use of evidence in pharmacovigilance: Case reports as the reference source for drug withdrawals
-
Arnaiz JA, Carne X, Riba N, et al. The use of evidence in pharmacovigilance: case reports as the reference source for drug withdrawals. Eur J Clin Pharmacol 2001; 57 (1): 89-91
-
(2001)
Eur J Clin Pharmacol
, vol.57
, Issue.1
, pp. 89-91
-
-
Arnaiz, J.A.1
Carne, X.2
Riba, N.3
-
11
-
-
0036570099
-
Timing of new black box warnings and withdrawals for prescription medications
-
Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287 (17): 2215-20
-
(2002)
JAMA
, vol.287
, Issue.17
, pp. 2215-2220
-
-
Lasser, K.E.1
Allen, P.D.2
Woolhandler, S.J.3
-
12
-
-
32244432294
-
An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets
-
Clarke A, Deeks JJ, Shakir SA. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets. Drug Saf 2006; 29 (2): 175-81
-
(2006)
Drug Saf
, vol.29
, Issue.2
, pp. 175-181
-
-
Clarke, A.1
Deeks, J.J.2
Shakir, S.A.3
-
13
-
-
33751071330
-
The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France
-
Olivier P, Montastruc JL. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. Pharmacoepidemiol Drug Saf 2006; 15 (11): 808-12
-
(2006)
Pharmacoepidemiol Drug Saf
, vol.15
, Issue.11
, pp. 808-812
-
-
Olivier, P.1
Montastruc, J.L.2
-
14
-
-
37249007168
-
-
European Medicines Agency [online] [Accessed 2011 Jul 12]
-
European Medicines Agency. EPARs for authorised medicinal products for human use [online]. Available from URL: http://www.ema.europa.eu/htms/human/ epar/a.htm. [Accessed 2011 Jul 12]
-
EPARs for Authorised Medicinal Products for Human Use
-
-
-
15
-
-
84968762251
-
-
European Commission [online] [Accessed 2011 Aug 2]
-
European Commission. The Community Register of medicinal products [online]. Available from URL: http://ec. europa.eu/enterprise/sectors/ pharmaceuticals/documents/ community-register/index-en.htm [Accessed 2011 Aug 2]
-
The Community Register of Medicinal Products
-
-
-
16
-
-
84859819874
-
-
WHO Collaborating Centre for Drug Statistics Methodology 18-06-2011
-
WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2 10-05-2011; 18-06-2011
-
ATC/DDD Index 2 10-05-2011
-
-
-
17
-
-
33748675101
-
-
European Commission (revision 2) [online] [Accessed 2011 Aug 2]
-
European Commission (2009). A guideline on summary of product characteristics (revision 2) [online]. Available from URL: http://ec.europa.eu/ health/files/eudralex/vol-2/c/smpc-guideline-rev2-en.pdf [Accessed 2011 Aug 2]
-
(2009)
A Guideline on Summary of Product Characteristics
-
-
-
18
-
-
84859838574
-
Commission regulation (EC) No 1234/2
-
European Commission 12/12/2008 [online] [Accessed 2011 Aug 2]
-
European Commission (2008). Commission regulation (EC) No 1234/2 Official Journal L 334, 12/12/2008, pp. 7-24 [online] Available from URL: http://ec.europa.eu/health/ files/eudralex/vol-1/reg-2008-1234/reg-2008-1234-en. pdf [Accessed 2011 Aug 2]
-
(2008)
Official Journal L
, vol.334
, pp. 7-24
-
-
-
19
-
-
77955551374
-
Risk management plans: Are they a tool for improving drug safety?
-
Frau S, Font Pous M, Luppino MR, et al. Risk management plans: are they a tool for improving drug safety? Eur J Clin Pharmacol 2010; 66 (8): 785-90
-
(2010)
Eur J Clin Pharmacol
, vol.66
, Issue.8
, pp. 785-790
-
-
Frau, S.1
Font Pous, M.2
Luppino, M.R.3
-
20
-
-
67449144386
-
European biologicals registers: Methodology, selected results and perspectives
-
Zink A, Askling J, Dixon WG, et al. European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 2009; 68 (8): 1240-6
-
(2009)
Ann Rheum Dis
, vol.68
, Issue.8
, pp. 1240-1246
-
-
Zink, A.1
Askling, J.2
Dixon, W.G.3
-
21
-
-
0036593951
-
Preclinical safety evaluation of biotechnology- derived pharmaceuticals
-
Cavagnaro JA. Preclinical safety evaluation of biotechnology- derived pharmaceuticals. Nat Rev Drug Discov 2002; 1 (6): 469-75
-
(2002)
Nat Rev Drug Discov
, vol.1
, Issue.6
, pp. 469-475
-
-
Cavagnaro, J.A.1
-
22
-
-
77952819564
-
Validation of statistical signal detection procedures in eudravigilance post-authorization data: A retrospective evaluation of the potential for earlier signaling
-
Alvarez Y, Hidalgo A, Maignen F, et al. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling. Drug Saf 2010; 33 (6): 475-87
-
(2010)
Drug Saf
, vol.33
, Issue.6
, pp. 475-487
-
-
Alvarez, Y.1
Hidalgo, A.2
Maignen, F.3
-
23
-
-
57949092897
-
The politics and bio-ethics of regulatory trust: Case-studies of pharmaceuticals
-
Abraham J. The politics and bio-ethics of regulatory trust: case-studies of pharmaceuticals. Med Health Care Philos 2008; 11 (4): 415-26
-
(2008)
Med Health Care Philos
, vol.11
, Issue.4
, pp. 415-426
-
-
Abraham, J.1
-
24
-
-
84881264406
-
Europes opportunity to open up drug regulation
-
Garattini S, Bertele V. Europes opportunity to open up drug regulation. BMJ 2010; 340: c1578
-
BMJ
, vol.2010
, Issue.340
-
-
Garattini, S.1
Bertele, V.2
-
25
-
-
84859876801
-
The FDA and the black arts of drug regulation
-
Rawlins M. The FDA and the black arts of drug regulation. Lancet 2010; 376 (9751): 1455-6
-
(2010)
Lancet
, vol.376
, Issue.9751
, pp. 1455-1456
-
-
Rawlins, M.1
-
26
-
-
77951074523
-
Improving pharmacovigilance in Europe
-
MooreN, Begaud B. Improving pharmacovigilance in Europe. BMJ 2010; 340: c1694
-
(2010)
BMJ
, vol.340
-
-
Moore, N.1
Begaud, B.2
-
27
-
-
77958008305
-
Evaluation of benefit-risk
-
Garattini S. Evaluation of benefit-risk. Pharmacoeconomics 2010; 28 (11): 981-6
-
(2010)
Pharmacoeconomics
, vol.28
, Issue.11
, pp. 981-986
-
-
Garattini, S.1
-
29
-
-
78049521348
-
Using market-exclusivity incentives to promote pharmaceutical innovation
-
Kesselheim AS. Using market-exclusivity incentives to promote pharmaceutical innovation. N Engl J Med 2010; 363 (19): 1855-62
-
(2010)
N Engl J Med
, vol.363
, Issue.19
, pp. 1855-1862
-
-
Kesselheim, A.S.1
|